The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Plasma Protease C1-inhibitor Treatment Market Research Report 2024
Synopsis
This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.
The global Plasma Protease C1-inhibitor Treatment market was valued at US$ 2194.9 million in 2023 and is anticipated to reach US$ 3431.7 million by 2030, witnessing a CAGR of 6.6% during the forecast period 2024-2030.
Based on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients.
This report aims to provide a comprehensive presentation of the global market for Plasma Protease C1-inhibitor Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasma Protease C1-inhibitor Treatment.
Report Scope
The Plasma Protease C1-inhibitor Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Plasma Protease C1-inhibitor Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Plasma Protease C1-inhibitor Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
CSL
Sanquin
Pharming Group
Segment by Type
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)
Segment by Application
Hospital Pharmacies
Independent Pharmacies and Outlets
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Plasma Protease C1-inhibitor Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.
The global Plasma Protease C1-inhibitor Treatment market was valued at US$ 2194.9 million in 2023 and is anticipated to reach US$ 3431.7 million by 2030, witnessing a CAGR of 6.6% during the forecast period 2024-2030.
Based on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients.
This report aims to provide a comprehensive presentation of the global market for Plasma Protease C1-inhibitor Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasma Protease C1-inhibitor Treatment.
Report Scope
The Plasma Protease C1-inhibitor Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Plasma Protease C1-inhibitor Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Plasma Protease C1-inhibitor Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
CSL
Sanquin
Pharming Group
Segment by Type
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)
Segment by Application
Hospital Pharmacies
Independent Pharmacies and Outlets
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Plasma Protease C1-inhibitor Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Plasma Protease C1-inhibitor Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 C1-inhibitors
1.2.3 Kallikrein Inhibitor (Kalbitor)
1.3 Market by Application
1.3.1 Global Plasma Protease C1-inhibitor Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Independent Pharmacies and Outlets
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Plasma Protease C1-inhibitor Treatment Market Perspective (2019-2030)
2.2 Plasma Protease C1-inhibitor Treatment Growth Trends by Region
2.2.1 Global Plasma Protease C1-inhibitor Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Plasma Protease C1-inhibitor Treatment Historic Market Size by Region (2019-2024)
2.2.3 Plasma Protease C1-inhibitor Treatment Forecasted Market Size by Region (2025-2030)
2.3 Plasma Protease C1-inhibitor Treatment Market Dynamics
2.3.1 Plasma Protease C1-inhibitor Treatment Industry Trends
2.3.2 Plasma Protease C1-inhibitor Treatment Market Drivers
2.3.3 Plasma Protease C1-inhibitor Treatment Market Challenges
2.3.4 Plasma Protease C1-inhibitor Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Plasma Protease C1-inhibitor Treatment Players by Revenue
3.1.1 Global Top Plasma Protease C1-inhibitor Treatment Players by Revenue (2019-2024)
3.1.2 Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Plasma Protease C1-inhibitor Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Plasma Protease C1-inhibitor Treatment Revenue
3.4 Global Plasma Protease C1-inhibitor Treatment Market Concentration Ratio
3.4.1 Global Plasma Protease C1-inhibitor Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Plasma Protease C1-inhibitor Treatment Revenue in 2023
3.5 Plasma Protease C1-inhibitor Treatment Key Players Head office and Area Served
3.6 Key Players Plasma Protease C1-inhibitor Treatment Product Solution and Service
3.7 Date of Enter into Plasma Protease C1-inhibitor Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Plasma Protease C1-inhibitor Treatment Breakdown Data by Type
4.1 Global Plasma Protease C1-inhibitor Treatment Historic Market Size by Type (2019-2024)
4.2 Global Plasma Protease C1-inhibitor Treatment Forecasted Market Size by Type (2025-2030)
5 Plasma Protease C1-inhibitor Treatment Breakdown Data by Application
5.1 Global Plasma Protease C1-inhibitor Treatment Historic Market Size by Application (2019-2024)
5.2 Global Plasma Protease C1-inhibitor Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Plasma Protease C1-inhibitor Treatment Market Size (2019-2030)
6.2 North America Plasma Protease C1-inhibitor Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Plasma Protease C1-inhibitor Treatment Market Size by Country (2019-2024)
6.4 North America Plasma Protease C1-inhibitor Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Plasma Protease C1-inhibitor Treatment Market Size (2019-2030)
7.2 Europe Plasma Protease C1-inhibitor Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Plasma Protease C1-inhibitor Treatment Market Size by Country (2019-2024)
7.4 Europe Plasma Protease C1-inhibitor Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Plasma Protease C1-inhibitor Treatment Market Size (2019-2030)
8.2 Asia-Pacific Plasma Protease C1-inhibitor Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Plasma Protease C1-inhibitor Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Plasma Protease C1-inhibitor Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Plasma Protease C1-inhibitor Treatment Market Size (2019-2030)
9.2 Latin America Plasma Protease C1-inhibitor Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Plasma Protease C1-inhibitor Treatment Market Size by Country (2019-2024)
9.4 Latin America Plasma Protease C1-inhibitor Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Size (2019-2030)
10.2 Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Detail
11.1.2 Takeda Business Overview
11.1.3 Takeda Plasma Protease C1-inhibitor Treatment Introduction
11.1.4 Takeda Revenue in Plasma Protease C1-inhibitor Treatment Business (2019-2024)
11.1.5 Takeda Recent Development
11.2 CSL
11.2.1 CSL Company Detail
11.2.2 CSL Business Overview
11.2.3 CSL Plasma Protease C1-inhibitor Treatment Introduction
11.2.4 CSL Revenue in Plasma Protease C1-inhibitor Treatment Business (2019-2024)
11.2.5 CSL Recent Development
11.3 Sanquin
11.3.1 Sanquin Company Detail
11.3.2 Sanquin Business Overview
11.3.3 Sanquin Plasma Protease C1-inhibitor Treatment Introduction
11.3.4 Sanquin Revenue in Plasma Protease C1-inhibitor Treatment Business (2019-2024)
11.3.5 Sanquin Recent Development
11.4 Pharming Group
11.4.1 Pharming Group Company Detail
11.4.2 Pharming Group Business Overview
11.4.3 Pharming Group Plasma Protease C1-inhibitor Treatment Introduction
11.4.4 Pharming Group Revenue in Plasma Protease C1-inhibitor Treatment Business (2019-2024)
11.4.5 Pharming Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
